Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

3SBio Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

06 Feb 2016 Reuters Investment Profile 12 $20.00

3SBio Inc. (1530) - Strategic SWOT Analysis Review

3SBio Inc. (1530) - Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is one of the leading biotechnology companies i...

08 Feb 2016 GlobalData 56 $300.00

Trading Report for (SSRX). A detailed report, including free correlated market analysis, and updates.

Detailed Trading Report for SSRX. Entry levels, target prices, and risk controls are integral. In addition, free market anal...

08 Feb 2016 Stock Traders Daily 5 $20.00

Thomson Reuters Stock Report - 3SBio Inc (1530-HK)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

05 Feb 2016 Thomson Reuters Stock Report 11 $25.00

Wright Investors Service Comprehensive Report for 3sbio Inc

Quantitative analyses of financial statements (Income Statement, Balance Sheet and Sources of Capital), extensive ratio table...

22 Jan 2016 Wright Reports 55 $75.00

3SBio Inc. (1530) - Strategic SWOT Analysis Review

3SBio Inc. (1530) - Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is one of the leading biotechnology companies i...

07 Dec 2015 GlobalData 55 $300.00

3SBio Inc. (1530) - Strategic SWOT Analysis Review

3SBio Inc. (1530) - Strategic SWOT Analysis Review Summary 3SBio Inc. (3SBio) is one of the leading biotechnology compa...

18 Sep 2015 GlobalData 27 $125.00

3SBIO INC.-截 至 二 零 一 五 年 六 月 三 十 日 止 六 個 月 中 期 業 績 公 告

21 Aug 2015 Guotai JunAn (HK) Research 26 $253.00

京 華 山 一 [三 生 製 藥(1530 HK) - 無評級: 具賣點的新上市生物藥股] (06/12/2015)

最新發展 生物製藥領軍企業三生製藥今起在港交所掛牌上市。 催化劑 專利藥增長前景強勁。旗艦藥品益比奧和特比澳分別用於治療貧血和血小板減少。這兩產品佔14年度總收入52%/39%,到14年度的兩年復合增長為26%/45%。益比奧是中國重組人促...

11 Jun 2015 Core Pacific - Yamaichi International (H.K.) Limited 2 $23.00

Core Pacific - Yamaichi [3SBio (1530 HK) : NOT RATED - New biopharm listing with niches] (06/11/2015)

What’s New 3SBio, a biopharmaceutical leader, begins to trade on HKEx today. Catalyst Proprietary drugs with strong ...

10 Jun 2015 Core Pacific - Yamaichi International (H.K.) Limited 2 $23.00